Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7977MR)

This product GTTS-WQ7977MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7977MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ919MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ8376MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ10827MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ2600MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ13675MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ1579MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ10883MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ10270MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFG 316
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW